Crystal Structures of PI3Kα Complexed with PI103 and Its Derivatives: New Directions for Inhibitors Design.

The phosphatidylinositol 3-kinase (PI3K) signaling pathway plays important roles in cell proliferation, growth, and survival. Hyperactivated PI3K is frequently found in a wide variety of human cancers, validating it as a promising target for cancer therapy. We determined the crystal structure of the human PI3Kα-PI103 complex to unravel molecular interactions. Based on the structure, substitution at the R1 position of the phenol portion of PI103 was demonstrated to improve binding affinity via forming a new H-bond with Lys802 at the bottom of the ATP catalytic site. Interestingly, the crystal structure of the PI3Kα-9d complex revealed that the flexibility of Lys802 can also induce additional space at the catalytic site for further modification. Thus, these crystal structures provide a molecular basis for the strong and specific interactions and demonstrate the important role of Lys802 in the design of novel PI3Kα inhibitors.

[1]  Emilio Hirsch,et al.  Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis , 2005, Nature Medicine.

[2]  J. Tamburini,et al.  PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies , 2012, Current Oncology Reports.

[3]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[4]  D. Durden,et al.  PI-3 kinase-PTEN signaling node: an intercept point for the control of angiogenesis. , 2009, Current pharmaceutical design.

[5]  Bert Vogelstein,et al.  The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations , 2007, Science.

[6]  S. Ward,et al.  Inhibition of PI3K Signaling Spurs New Therapeutic Opportunities in Inflammatory/Autoimmune Diseases and Hematological Malignancies , 2012, Pharmacological Reviews.

[7]  L. Mario Amzel,et al.  The Structure of a Human p 110 a / p 85 a Complex Elucidates the Effects of Oncogenic PI 3 K a Mutations , 2007 .

[8]  K. Kinzler,et al.  A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane , 2009, Proceedings of the National Academy of Sciences.

[9]  Robbie Loewith,et al.  A pharmacological map of the PI3-K family defines a role for p110 alpha in signaling: The structure of complex of phosphoinositide 3- kinase gamma with inhibitor PIK-39 , 2006 .

[10]  Roger L. Williams,et al.  Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases , 2011, Oncogene.

[11]  M. Brattain,et al.  Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: which way shall we go? , 2011, Current medicinal chemistry.

[12]  W. Denny.  Phosphoinositide 3-kinase α inhibitors: a patent review , 2013, Expert opinion on therapeutic patents.

[13]  Peter J. Alaimo,et al.  Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. , 2004, Bioorganic & medicinal chemistry.

[14]  K. Shokat,et al.  A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. , 2007, Cancer research.

[15]  William A Weiss,et al.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.

[16]  Yingwei Chen,et al.  PI3K: A potential therapeutic target for cancer , 2012, Journal of cellular physiology.

[17]  Michael A Davies,et al.  The role of the PI3K-AKT pathway in melanoma. , 2012, Cancer journal.

[18]  Juswinder Singh,et al.  Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα. , 2013, Journal of medicinal chemistry.